drugset
drugset / Trial / NCT01664897

Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT01664897 ↗

Phase 2 Completed 29 enrolled M.D. Anderson Cancer Center Astellas Pharma Inc · collabNational Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

This pilot phase II trial studies how well erlotinib hydrochloride works in treating patients with relapsed or refractory acute myeloid leukemia. Erlotinib hydrochloride may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Timeline

Start
2013-05-16
Primary completion
2018-10-25
Completion
2018-10-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Erlotinib Small molecule — Oral

Indications

acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent acute myeloid leukemia with t(9;11)(p22;q23) acute myeloid leukemia, inv(16)(p13.1;q22) acute myeloid leukemia, t(16;16)(p13.1;q22) acute myeloid leukemia, t(8;21)(q22; q22.1) acute promyelocytic leukemia chronic myelomonocytic leukemia myelodysplastic syndrome